Alerts

We are advising that Movectro (cladribine) has been withdrawn from supply in Australia due to commercial reasons.

We are reviewing the safety of the Pneumovax 23 vaccine due to reports of severe local reactions and have updated our revaccination recommendations.

Concerns have been expressed that a range of breast screening devices based on technologies other than mammography have not been appropriately assessed for their safety or accuracy.

On 26 January 2011, the US Food and Drug Administration (FDA) announced a safety communication to warn about an association between breast implants and anaplastic large cell lymphoma. The risk of a patient developing this type of lymphoma is very low.

Seasonal flu vaccine: Response to the West Australian (Stokes) Review

Do not use So Hard for Men tablets, Shaguar tablets, and Pulse8 for Women capsules as they contain undeclared tadalafil and are not approved. Consult your doctor if you have concerns.

About Brachytherapy kits (regulatory status)

The national immunisation program with Panvax® began on 30 September 2009. The TGA has been closely monitoring any side effects from the use of the vaccine.

The TGA is aware that the French authorities have now released an updated statement in regard to the testing of the PIP implants:

We are analysing the safety of the Panvax H1N1 vaccine following reports of febrile convulsions in children.

We are investigating febrile reactions in young children following the 2010 flu vaccine and have paused its use for kids under 5 in Western Australia.

Testing on Australian Poly Implant Prothèse (PIP) samples of implants has been undertaken by TGA